NSCLC, metastaticCheckMate 026: a phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC - Socinski, Mark A.; Steins, Martin (Annals of oncology, 2016)
Gesehen am 10.11.2017